In re application of: Tikva Vogel et al.

Serial No.: 09/492,971

JUN 2 2 2000

Filed: January 27, 2000

TECH CENTER 1600/2900

For: FIBRIN BINDING DOMAIN POLYPEPTIDES AND USES AND METHODS OF PRODUCING SAME

HONORABLE ASSISTANT COMMISSIONER FOR PATENTS   June 16, 2000
Washington, D.C. 20231

S I R:

Transmitted herewith is an amendment to the above-identified application.

_____ Small entity status of this application under 37 C.F.R. § 1.9 and § 1.27 has been established by a verified statement previously submitted.

_____ a verified statement to establish small entity status under 37 C.F.R. § 1.9 and § 1.27 is enclosed.

___X___ No additional fee is required.

The filing fee is calculated as follows:

| | NUMBER AFTER AMENDMENT | | HIGHEST NUMBER PREVIOUSLY PAID FOR | | NUMBER OF EXTRA CLAIMS PRESENTED | | RATE | | FEE | |
							SMALL ENTITY	OTHER ENTITY	SMALL ENTITY	OTHER ENTITY
Total Claims	9	–	* 20	=	*** 0	x	9	18	= 0	0
Independent Claims	2	–	** 3	=	*** 0	x	39	78	= 0	0
Multiple Dependent Claims(s) Presented ____ Yes _X_ No For First Time:							130	260	0	0
					TOTAL ADDITIONAL FEE				$ 0.00	

*If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 20, write "20" in this space.

**If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 3, write "3" in this space.

***If the difference between the "NUMBER AFTER AMENDMENT" and the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is l ss than "0", writ "0" in the space.

Applicants: Tikva Vogel et al.
Serial No: 09/49●●71
Filed: January 27, 2000

Amendment Transmittal Letter
Page 2

June 16, 2000

JUN 2 2 2000

TECH CENTER 1600/2900

The "HIGHEST NUMBER PREVIOUSLY PAID FOR" (Total or
Independent) is the highest of the "NUMBER AFTER
AMENDMENT" in any prior amendment or the number
of claims as originally filed.

_____ Please charge Deposit Account No. _____
in the amount of $_____.

_____ A check in the amount of $_____ is enclosed.

__X__ The Commissioner is hereby authorized to charge
payment of the following fees associated with
this communication or credit any overpayment to
Deposit Account No. 03-3125 . Three
copies of this sheet are enclosed.

__X__ Any filing fees under 37 C.F.R. §1.16 for the
presentation of extra claims.

__X__ Any patent application processing fees under
37 C.F.R. §1.17.

Respectfully submitted,

John R. White
Registration No. 28,678
Attorney for Applicant(s)
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence
is being deposited this date with the U.S.
Postal Service with sufficient postage as
first class mail in an envelope addressed
to: Assistant Commissioner for Patents,
Washington, D.C. 20231.

John P. White   6/16/00
John P. White   Date
Reg. No. 28,678

OIPE JC133
JUN 1 9 2000
PATENT & TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Tikva Vogel et al.

Serial No.:   09/492,971   Examiner: E. Longton

Filed   :   January 27, 2000   Group Art Unit: Not Yet Known

For   :   FIBRIN BINDING DOMAIN POLYPEPTIDES AND USES AND
                METHODS OF PRODUCING SAME

                                    1185 Avenue of the Americas
                                    New York, New York 10036
                                    June 16, 2000

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

SECOND PRELIMINARY AMENDMENT IN
RESPONSE TO EXAMINER'S MAY 11, 2000 TELEPHONE
CONFERENCE AND INFORMATION DISCLOSURE STATEMENT

This Second Preliminary Amendment is submitted in response to a
May 11, 2000 telephone conference between the Examiner assigned to
the above-identified application and Elizabeth Wieckowski, an
associate of the office of the attorneys of record, in connection
with the above-identified application.

On January 27, 2000, applicants filed the subject application. On
May 11, 2000 the Examiner called to suggest amending the claims to
include amino acid sequence information or length limitations.

Please amend the above-identified application as follows:

In the Claims

In accordance with 37 C.F.R. §1.121(b), please amend claim 88 by
adding the underlined material and deleting the bracketed material
as follows:

88.   (Amended) An imaging agent which comprises a polypeptide
         labeled   with   an   imageable   marker,   [wherein   the